In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ZAI Lab brings in over $100mm through Series B round

Executive Summary

Chinese biotech Zai Lab Ltd. raised over $100mm through its Series B round. Advantech Capital led and was joined by OrbiMed and returning backers Qiming Ventures, Sequoia Capital China, and TF Capital. The funding will support ZAI's pipeline of candidates in development for cancer (including a NSCLC compound licensed from Hanmi late last year), asthma, COPD, IBD, and graft-versus-host disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies